Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
Open Access
- 1 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BioDrugs
- Vol. 34 (2), 183-196
- https://doi.org/10.1007/s40259-020-00406-1
Abstract
Objectives The aims were to demonstrate pharmacokinetic (PK) similarity between DRL_RI, a proposed rituximab biosimilar, and two reference innovator products (Rituxan(R) [RTX-US] and MabThera(R) [RTX-EU]) and compare their pharmacodynamics (PD), efficacy, safety, and immunogenicity in rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX)-based therapy and no prior biologic administration. Methods In this randomized, double-blind, parallel-group study, 276 patients with moderate-to-severe active RA were randomized to receive DRL_RI, RTX-US, or RTX-EU on days 1 and 15. The primary PK end points included area under the concentration-time curve from time 0 to 336 h after first infusion (AUC(0-14 days, first infusion)), AUC from day 1 through week 16 (AUC(0-infinity, entire course)), and AUC from time 0 to time of last quantifiable concentration after the second dose (AUC(0-t, second infusion)). Secondary end points included other PK parameters, such as maximum concentration (C-max), time to C-max after each infusion, terminal half-life, systemic clearance, and volume of distribution after the second infusion; PD parameters and efficacy until week 24; safety and immunogenicity at week 24 and 52; and B cell recovery until week 52. AUC from time 0 to time of last quantifiable concentration after the first dose and over the entire course from day 1 through week 16 (AUC(0-t, entire course)) was analyzed as an exploratory end point. Results The 91% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the primary end point of AUC(0-infinity, entire course) were within the bioequivalence limits of 80-125% for all comparisons: DRL_RI versus RTX-US 100.37% (92.30-109.14), DRL_RI versus RTX-EU 93.58% (85.98-101.85), and RTX-US versus RTX-EU 93.24% (85.62-101.54). PD outcomes (peripheral blood B-cell depletion and mean change in Disease Activity Score [28 joints]-C-reactive protein), efficacy, safety, and immunogenicity were also comparable between DRL_RI and the reference products. Conclusion DRL_RI, a proposed biosimilar, demonstrated three-way PK similarity with RTX-EU and RTX-US, the reference innovator products, with comparable efficacy, PD, safety, and immunogenicity.Funding Information
- This study was funded by Dr Reddy's Laboratories
This publication has 19 references indexed in Scilit:
- Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trialmAbs, 2018
- A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2016
- A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritisBritish Journal of Clinical Pharmacology, 2016
- The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 studyAnnals Of The Rheumatic Diseases, 2014
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics, 2011
- Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))Annals Of The Rheumatic Diseases, 2010
- Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical TrialThe Journal of Clinical Pharmacology, 2005
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- The role of internal pilot studies in increasing the efficiency of clinical trialsStatistics in Medicine, 1990
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980